Vaginal Isonicotinic Acid Hydrazide Administration Prior to Intrauterine Device Insertion

Benefits of Self-administered Vaginal Isonicotinic Acid Hydrazide (INH) Administration 12 Hours Prior to Intrauterine Device Insertion in Adolescent and Young Women: a Randomized Controlled Trial

To investigate whether vaginal isonicotinic acid hydrazide administered before the levonorgestrel-releasing intrauterine system insertion reduces IUD insertion pain and difficulty in insertion in adolescents and young women.

Long-acting reversible contraception methods are highly effective methods for reduction of the unplanned pregnancy rate worldwide. The intrauterine device is a single procedure that provides reliable, effective and long term contraception for many women. However, the insertion procedure can be associated with a troublesome degree of pain that prevent some women from choosing its use. Different interventions have been described to decrease pain perception during intrauterine device insertion with no agreement on an effective one.

Inclusion Criteria:

• nulliparous adolescent and young women requesting levonorgestrel-releasing intrauterine device

Exclusion Criteria:

• pregnancy and
• contraindication or allergy to or contraindication to IUD insertion,
• chronic pelvic pain,
• pelvic inflammatory disease,
• analgesic intake 24 hours prior to IUD insertion.